{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007002","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.542569+00:00","generated_at":"2026-06-18T06:41:10.806695+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"aTyr Pharma FY2022 cash $69.3M; Phase 3 EFZO-FIT enrolling globally; $52M Feb offering extends runway to 2026","bullets":["Cash & investments $69.3M at Dec 31, 2022; Feb 2023 offering raised ~$52M gross plus $10M milestone from Kyorin; runway into 2026.","R&D expense $42.8M, G&A $14.0M for full year 2022; pre-revenue biotech with no product sales.","Phase 3 EFZO-FIT (sarcoidosis) enrolling in U.S., Europe, Japan; Kyorin dosed first patient in Japan triggering $10M milestone.","FDA cleared IND for Phase 2 proof-of-concept SSc-ILD study; EU orphan designation for efzofitimod in sarcoidosis.","LTBP1 identified as target of DARS domain; European patent allowance for efzofitimod + pirfenidone combo."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007002","json":"https://secwatch.observer/filing/0000950170-23-007002.json","markdown":"https://secwatch.observer/filing/0000950170-23-007002.md","text":"https://secwatch.observer/filing/0000950170-23-007002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023007002/0000950170-23-007002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023007002/life-20230309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T06:41:10.806695+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b0287927d6a0936c0c7ea75859085c9455839a00","claim":"aTYR PHARMA INC reported financial results for year ended December 31, 2022.","evidence_excerpt":"On March 9, 2023, aTyr Pharma, Inc. issued a press release announcing financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023007002/0000950170-23-007002-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}